MX2020013181A - Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona. - Google Patents
Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.Info
- Publication number
- MX2020013181A MX2020013181A MX2020013181A MX2020013181A MX2020013181A MX 2020013181 A MX2020013181 A MX 2020013181A MX 2020013181 A MX2020013181 A MX 2020013181A MX 2020013181 A MX2020013181 A MX 2020013181A MX 2020013181 A MX2020013181 A MX 2020013181A
- Authority
- MX
- Mexico
- Prior art keywords
- administering
- compound
- patient
- dione
- pyridin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382398 | 2018-06-06 | ||
| PCT/IB2019/054743 WO2019234689A1 (en) | 2018-06-06 | 2019-06-06 | Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013181A true MX2020013181A (es) | 2021-02-26 |
Family
ID=62716009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013181A MX2020013181A (es) | 2018-06-06 | 2019-06-06 | Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12673048B2 (enExample) |
| EP (1) | EP3801516A1 (enExample) |
| JP (1) | JP7549344B2 (enExample) |
| KR (1) | KR20210031435A (enExample) |
| CN (1) | CN112512524A (enExample) |
| AU (1) | AU2019283649A1 (enExample) |
| BR (1) | BR112020024917A2 (enExample) |
| CA (1) | CA3102407A1 (enExample) |
| CL (1) | CL2020003162A1 (enExample) |
| EA (1) | EA202092953A1 (enExample) |
| IL (1) | IL279183A (enExample) |
| MX (1) | MX2020013181A (enExample) |
| SG (1) | SG11202012045UA (enExample) |
| WO (1) | WO2019234689A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| HUE071482T2 (hu) | 2018-06-06 | 2025-08-28 | Minoryx Therapeutics S L | (5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]-fenil]metil]-1,3-tiazolidin-2,4- dion és sói mitokondriális betegségek kezelésében vagy megelõzésében történõ alkalmazásra |
| JP2026500743A (ja) | 2022-12-28 | 2026-01-08 | ミノリックス セラピューティクス エセ．エレ． | レリグリタゾンの最適投薬 |
| WO2024231881A2 (en) | 2023-05-09 | 2024-11-14 | Minoryx Therapeutics S.L. | Polymorphic forms and formulations of leriglitazone |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8589175B2 (en) * | 2005-11-29 | 2013-11-19 | Children's Hospital Medical Center | Optimization and individualization of medication selection and dosing |
| WO2013040419A1 (en) | 2011-09-14 | 2013-03-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating hyperprolinemia-associated mental disorders |
| US20140114676A1 (en) * | 2012-10-23 | 2014-04-24 | Theranos, Inc. | Drug Monitoring and Regulation Systems and Methods |
| NZ725492A (en) * | 2014-04-02 | 2023-06-30 | Minoryx Therapeutics S L | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
| MX379710B (es) | 2016-12-01 | 2025-03-11 | Minoryx Therapeutics S L | 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-tiazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico. |
| CN110198945B (zh) | 2016-12-23 | 2023-06-27 | 米尼奥尔克斯治疗有限公司 | 用于制备噻唑烷二酮化合物及其盐的方法 |
| HUE071482T2 (hu) | 2018-06-06 | 2025-08-28 | Minoryx Therapeutics S L | (5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]-fenil]metil]-1,3-tiazolidin-2,4- dion és sói mitokondriális betegségek kezelésében vagy megelõzésében történõ alkalmazásra |
| MX2020013182A (es) | 2018-06-06 | 2021-02-26 | Minoryx Therapeutics S L | Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales. |
| CN116390725A (zh) | 2020-04-30 | 2023-07-04 | 米尼奥尔克斯治疗有限公司 | 用于治疗肺部炎症和间质性肺病的羟基吡格列酮 |
-
2019
- 2019-06-06 MX MX2020013181A patent/MX2020013181A/es unknown
- 2019-06-06 CA CA3102407A patent/CA3102407A1/en active Pending
- 2019-06-06 CN CN201980046617.8A patent/CN112512524A/zh active Pending
- 2019-06-06 AU AU2019283649A patent/AU2019283649A1/en not_active Abandoned
- 2019-06-06 EA EA202092953A patent/EA202092953A1/ru unknown
- 2019-06-06 BR BR112020024917-3A patent/BR112020024917A2/pt not_active Application Discontinuation
- 2019-06-06 US US16/972,368 patent/US12673048B2/en active Active
- 2019-06-06 EP EP19742912.9A patent/EP3801516A1/en active Pending
- 2019-06-06 SG SG11202012045UA patent/SG11202012045UA/en unknown
- 2019-06-06 WO PCT/IB2019/054743 patent/WO2019234689A1/en not_active Ceased
- 2019-06-06 KR KR1020207037943A patent/KR20210031435A/ko not_active Abandoned
- 2019-06-06 JP JP2020567799A patent/JP7549344B2/ja active Active
-
2020
- 2020-12-03 IL IL279183A patent/IL279183A/en unknown
- 2020-12-04 CL CL2020003162A patent/CL2020003162A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2020003162A1 (es) | 2021-07-02 |
| CN112512524A (zh) | 2021-03-16 |
| SG11202012045UA (en) | 2021-01-28 |
| US12673048B2 (en) | 2026-07-07 |
| BR112020024917A2 (pt) | 2021-03-09 |
| JP2021527045A (ja) | 2021-10-11 |
| EP3801516A1 (en) | 2021-04-14 |
| JP7549344B2 (ja) | 2024-09-11 |
| WO2019234689A1 (en) | 2019-12-12 |
| CA3102407A1 (en) | 2019-12-12 |
| AU2019283649A1 (en) | 2021-01-07 |
| US20210308113A1 (en) | 2021-10-07 |
| EA202092953A1 (ru) | 2021-04-12 |
| IL279183A (en) | 2021-01-31 |
| KR20210031435A (ko) | 2021-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202092953A1 (ru) | Способ введения терапевтически эффективного количества 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-диона | |
| MX2022005812A (es) | Metodos de tratamiento de enfermedades y trastornos relacionados con desmetilasa 1 especifica de lisina con inhibidores de desmetilasa 1 especifica de lisina. | |
| CL2021000491A1 (es) | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas | |
| JP2005536475A5 (enExample) | ||
| CN106999475B (zh) | 异噁唑啉化合物用于治疗蠕形螨病的用途 | |
| CY1118651T1 (el) | Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη | |
| NZ604004A (en) | Pyridone and aza-pyridone compounds and methods of use | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| EA200601799A1 (ru) | Гидразидсодержащие соединения - ингибиторы cftr и их применение | |
| MX2020013182A (es) | Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales. | |
| IL172705A0 (en) | Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases | |
| CN107693518A (zh) | Ep‑4受体拮抗剂在治疗il‑23介导疾病中的用途 | |
| EA201991078A1 (ru) | Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3 | |
| CO5261586A1 (es) | Uso de pramipexol en el tratamiento de transtornos de adiccion | |
| NZ578928A (en) | Methods to increase mobility of hematopoietic stem cells by use of a lipopeptide compound and treatment of associated diseases | |
| MX2007014463A (es) | Metodos para tratar condiciones fibroticas. | |
| EP4545142A3 (en) | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases | |
| EP4520398A3 (en) | Treatment of prostate cancer | |
| MXPA04000839A (es) | Metodos y composiciones para el tratamiento de enfermedades oftalmicas. | |
| EA025948B1 (ru) | КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR | |
| JP2001522849A5 (enExample) | ||
| EA201991304A1 (ru) | 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-дион для лечения неалкогольной жировой болезни печени | |
| MX2022013021A (es) | Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial. | |
| JP2009532438A5 (enExample) | ||
| PL374301A1 (en) | Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment |